Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.
Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss ...
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.
Fortune on MSN2d
Danish town where weight-loss wonder drug Ozempic is made suffers from the highest rates of overweight children in DenmarkA more tragic irony in the town is an obesity crisis among residents living in the shadow of the massive Wegovy-making plant.
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...
Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback